Molecular Pathology of
Head and Neck Cancer
Head and Neck Cancer
|
Molecular Pathology of Head and Neck Cancer |
| Home | • | About | • | Our Team | • | Expert Opinion | • | CuraBase Workspace | • | Contact |
|
| Region | Incidence Overall | Incidence Males | Incidence Females | Deaths Overall | Deaths Males | Deaths Females |
|---|---|---|---|---|---|---|
| USA | 36540 | 25420 | 11120 | 7880 | 5430 | 2450 |
| Affected Protein | Pathway | Sub-Type | Ethnicity | Stage | Frequency (%) | Gene Amplification | Activating Mutation | Inactivating Mutation | Deletion | Promoter Hypermethylation | Comment | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C-Myc | Cell Cycle Regulation |
HNSCC | 9% | |||||||||
| Cyclin D1 | Cell Cycle Regulation |
primary head and neck squamous carcinomas | 34 - 37% | |||||||||
| EGFR (ErbB-1 receptor) | Receptor Tyrosine Kinase Signaling |
HNSCC | 7–19% | |||||||||
| Pi3-kinase | PI3-Kinase Signaling |
sporadic HNSCC | 11% | |||||||||
| PTEN | PI3-Kinase Signaling |
23% |
| See Clinical Trials in in the TTC Database |
| CANCER.GOV PDQ® - Standard Treatments for Head and Neck Cancer |